Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05991167 · ClinicalTrials.gov registry record

EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")

A clinical trial of ADHD, sponsored by Akili Interactive Labs.

Active
Registry status
150
Enrollment target
1
Study location

NCT05991167: Active study of ADHD, sponsored by Akili Interactive Labs.

NCT05991167 is a study of ADHD that is active but no longer recruiting, run by Akili Interactive Labs. The registered enrollment target is 150 participants, below the 188-participant average among 75 other ADHD trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05991167, a study of ADHD, is active but no longer recruiting, sponsored by Akili Interactive Labs.

ACTIVE NOT RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.

Conditions Studied

Interventions

  • DEVICE EndeavorRx

Study Locations (1)

Massachusetts

  • Akili Interactive Labs, Inc. - Boston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-06-01
Est. Completion 2025-12-31
Akili Interactive Labs

13 total trials

What the registry record for NCT05991167 still lists

NCT05991167 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 188-participant average among 75 other ADHD trials with a reported enrollment target (20% lower).

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which EndeavorRx is the first listed.

NCT05991167 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05991167 about?

NCT05991167 is a clinical study titled "EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")". The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.

What is the current status of trial NCT05991167?

This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2022-06-01. Estimated completion is 2025-12-31.

What conditions does trial NCT05991167 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT05991167?

The interventions under investigation include: EndeavorRx (DEVICE).

Who is sponsoring clinical trial NCT05991167?

This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05991167 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05991167's enrollment target sits among peer trials

150 25th of 75 higher than 51 of 75 other ADHD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05991167, the US trial registry maintained by the National Library of Medicine. NCT05991167 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.